tevimbra
(tislelizumab-jsgr)BEIGENE USA, INC.
Usage: TEVIMBRA is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (≥1), in combination with chemotherapy, or as a single agent after prior chemotherapy. It is also indicated for first-line treatment of HER2-negative gastric/gastroesophageal junction adenocarcinoma with PD-L1 expression.